Rafael Holdings Inc - Ordinary Shares - Class B
RFL
Market Cap$47.84M
Close$
$-0.26
115.1% downside
Current Fair Value
115.1% downsideOvervalued by 115.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $47.84 Million |
|---|---|
| Enterprise Value | $18.39 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.08 |
| Beta | 1.06 |
| Outstanding Shares | 23,777,493 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.66 |
|---|---|
| PEG | 1.94 |
| Price to Sales | - |
| Price to Book Ratio | 0.58 |
| Enterprise Value to Revenue | 25.12 |
| Enterprise Value to EBIT | -0.85 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.46 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Rafael Holdings Inc
57 employeesRafael Holdings is focused on development of novel cancer therapies. The Company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Through its wholly own...